ライフサイエンスコーパス: procarbazine

1 stered intravenously on days 1 to 3 replaced procarbazine.

2 isk, and modification of this association by procarbazine.

3 o received chemotherapy containing high-dose procarbazine.

4 c agents: cyclophosphamide, mitomycin C, and procarbazine.

5 , at best, a few weeks longer than that with procarbazine.

6 treating the parent xenograft D-245 MG with procarbazine.

7 01), ifosfamide (0.42, 0.23-0.79; p=0.0069), procarbazine (0.30, 0.20-0.46; p<0.0001) and cisplatin (

8 er, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosour

9 ) (day 1), etoposide 200 mg/m(2) (days 1-3), procarbazine 100 mg/m(2) (days 1-7), prednisone 40 mg/m(

10 ith five cycles of high-dose MTX 3.5 g/m(2), procarbazine 100 mg/m(2)/d, and vincristine 1.4 mg/m(2).

11 e 2 mg/m2 intravenously on days 1 and 8, and procarbazine 100 mg/m2 orally on days 1 to 14.

12 Procarbazine 100 mg/m2/d was administered for 7 days wit

13 istine (1.4 mg/m(2) intravenously on day 8), procarbazine (100 mg/m(2) orally on days 1-7), and predn

14 nitrogen mustard in addition to omission of procarbazine and melphalan.

15 therapy was assessed as cumulative doses for procarbazine and platinum agents, cyclophosphamide-equiv

16 ents, risks and benefits of exposure to both procarbazine and subdiaphragmatic radiotherapy should be

17 Increasing the dose of MTX and adding procarbazine and vincristine improved disease control an

18 ; or VAMP/cyclophosphamide, vincristine, and procarbazine) and involved-field radiation therapy deliv

19 eived two cycles of vincristine, prednisone, procarbazine, and doxorubicin or vincristine, prednisone

20 0.4%-12.6%) for patients who did not receive procarbazine, and increased 1.2-fold (95% CI, 1.1-1.3) f

21 les of methotrexate 2.5 g/m(2), vincristine, procarbazine, and intraventricular methotrexate (12 mg).

22 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (BEACOPP/BEACOPP14).

23 on as alternating chlorambucil, vinblastine, procarbazine, and prednisolone (ChlVPP) with prednisolon

24 , doxorubicin cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP [68%]), followed b

25 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP baseline) or four

26 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP(escalated)) in ear

27 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) had continuous am

28 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) was comparable to

29 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) and INRT (supe

30 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) significantly

31 e, the regimen of chlorambucil, vinblastine, procarbazine, and prednisone (ChlVPP) has been proposed

32 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for 6 cycles.

33 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for six cycles.

34 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escalated BEACOPP) plus tw

35 emotherapy was mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) or procarbazine, mec

36 ned to compare mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/doxorubicin, bleomyc

37 and etoposide/mechlorethamine, vincristine, procarbazine, and prednisone (ProMACE[day 1]-MOPP[day 8]

38 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPP] plus 2x ABVD).

39 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at baseline over ABVD was n

40 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone followed by 30.6 Gy involve

41 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the

42 e, etoposide, nitrogen mustard, vincristine, procarbazine, and prednisone in similar patient populati

43 , adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by two cycles of

44 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) has significantly improved

45 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) in newly diagnosed, advanc

46 , adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in the German Hodgkin Stud

47 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) on the fertility of male p

48 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) therapy was associated wit

49 apy with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone), ABVD (doxorubicin, bleomy

50 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and six cycles of COPP-EB

51 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone).

52 doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, menstrual activity was str

53 ess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consol

54 y with rituximab, methotrexate (3.5 g/m(2)), procarbazine, and vincristine (R-MPV).

55 s of induction chemotherapy (rituximab, MTX, procarbazine, and vincristine [R-MPV]) as follows: day 1

56 specially over 10 Gy), alkylating agents and procarbazine, at older ages, were significant risk facto

57 l signatures after treatment with or without procarbazine-containing chemotherapy (first study part);

58 Procarbazine-containing chemotherapy regimens are associ

59 lthy colon sample from patients who received procarbazine-containing chemotherapy.

60 clophosphamide, vincristine, prednisone, and procarbazine (COPP) and radiotherapy, but long-term trea

61 venous etoposide [day 1-3], 100 mg/m(2) oral procarbazine [day 1-7], 40 mg/m(2) oral prednisone [day

62 Colorectal SMN rates increased linearly with procarbazine dose (ERR per 1,000 mg/m(2) = 73.0 [95% CI,

63 A cumulative procarbazine dose of 4.3 g or more per square meter of b

64 For procarbazine dose, the IRR was 6.3 (95% CI, 3.0 to 13.2)

65 95% CI, 1.1-1.3) for each 1-g/m2 increase in procarbazine dose.

66 cancer rate became stronger with increasing procarbazine dose: the ERR per gray to the whole bowel w

67 to 46.6), after adjustment for radiation and procarbazine doses.

68 , high-dose methotrexate [MTX], vincristine, procarbazine) followed by a novel consolidation high-dos

69 ation to the stomach >/= 25 Gy and high-dose procarbazine (>/= 5,600 mg/m(2)) had strikingly elevated

70 he risk 7- to 8-fold, particularly following procarbazine, ifosfamide, and cyclophosphamide.

71 with independent contributions from each of procarbazine, ifosfamide, and cyclophosphamide.

72 When treating Hodgkin lymphoma, procarbazine in escalated-dose bleomycin-etoposide-doxor

73 iol treatment that protected the testis from procarbazine-induced damage.

74 Procarbazine induces a higher mutation burden and novel

75 strate here that giving a GnRH agonist after procarbazine injection also enhances spermatogenesis and

76 kylator (IRR, 4.8 [95% CI, 1.6 to 14.4]), or procarbazine (IRR, 16.9 [95% CI, 5.9 to 48.8]).

77 lts of this trial showed that treatment with procarbazine, lomustine (also called CCNU), and vincrist

78 Because procarbazine, lomustine (CCNU), and vincristine (PCV) is

79 atment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was ass

80 y; range 54 to 55 Gy) and nitrosourea-based (procarbazine, lomustine [CCNU], and vincristine [PCV-3 r

81 regimens involving alkylating agents such as procarbazine, lomustine, and carmustine.

82 rapy-carboplatin, vincristine, temozolomide, procarbazine, lomustine, and thioguanine-at age 4.5 year

83 se III clinical trial investigating adjuvant procarbazine, lomustine, and vincristine (PCV) chemother

84 e III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemother

85 sted a progression-free survival benefit for procarbazine, lomustine, and vincristine (PCV) chemother

86 udied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly

87 tients with AO/AOA were randomly assigned to procarbazine, lomustine, and vincristine (PCV) plus radi

88 our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TM

89 should be offered radiation therapy (RT) and procarbazine, lomustine, and vincristine (PCV).

90 51), the addition of neoadjuvant or adjuvant procarbazine, lomustine, and vincristine (PCV; respectiv

91 oplatin and vincristine (CV) or thioguanine, procarbazine, lomustine, and vincristine (TPCV).

92 stic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy.

93 Both temozolomide and the combination of procarbazine, lomustine, and vincristine provide surviva

94 iotherapy without vs with the combination of procarbazine, lomustine, and vincristine was 13.6% vs 37

95 The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy t

96 th carboplatin followed by chemotherapy with procarbazine, lomustine, and vincristine.

97 ith those who received radiation < 25 Gy and procarbazine < 5,600 mg/m(2) (Pinteraction < .001).

98 eived radiation to the stomach >/= 25 Gy but procarbazine < 5,600 mg/m(2); however, no procarbazine-r

99 tine, procarbazine, and prednisone (MOPP) or procarbazine, mechlorethamine, and vinblastine (PAVe) in

100 thamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma.

101 These agents include procarbazine, nitrogen mustard, melphalan, nitrosoureas

102 logues or steroids either before exposure to procarbazine or radiation or after irradiation enhances

103 ide-doxorubicin-cyclophosphamide-vincristine-procarbazine-prednisolone (eBEACOPP) is increasingly rep

104 mphoma treated with chlorambucil-vinblastine-procarbazine-prednisolone.

105 doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) are maturing with promising re

106 doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) in children with high-risk HL

107 ine (ABVD) and mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vi

108 of COPP/ABV (cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinbla

109 dacarbazine; cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinbla

110 ut procarbazine < 5,600 mg/m(2); however, no procarbazine-related risk was evident with radiation < 2

111 n addition to abdominal radiation, high-dose procarbazine (relative risk, 3.2 [CI, 1.1 to 9.4]) and p

112 1) and those who received more than 8.4 g/m2 procarbazine (RR, 2.5; 95% CI, 1.3-5.0).

113 tertile HR, 0.42; 95% CI, -0.31 to 0.57) or procarbazine (second tertile HR, 0.48; 95% CI, -0.26 to

114 aken orally on days 1 to 15; and 100 mg/m(2) procarbazine taken orally on days 1 to 15) or COPDAC, wh

115 D-245 MG xenografts were sensitive to procarbazine, temozolomide, N-methyl-N-nitrosourea, 1,3-

116 D-245 MG (PR) xenografts were resistant to procarbazine, temozolomide, N-methyl-N-nitrosourea, and

117 an, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin; CEC) in patien

118 e sex ratio and the association observed for procarbazine warrant further investigation.

119 n dose, and potential effect modification by procarbazine was explored.

120 clophosphamide, vincristine, prednisone, and procarbazine were added in TG2 (intermediate stages) or

121 However, replacing procarbazine with dacarbazine appears to mitigate gonada